Loading…
Annovis Bio, Inc. is projected to rise to $2.09 by 2027, a +19% move from its current price of $1.75. ANVS is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/3/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $1.70 | $1.75 | $1.80 | -0.01% |
| Aug 6 | $1.68 | $1.75 | $1.82 | -0.03% |
| Aug 7 | $1.67 | $1.75 | $1.83 | -0.04% |
| Aug 8 | $1.66 | $1.75 | $1.85 | -0.06% |
| Aug 9 | $1.65 | $1.75 | $1.86 | -0.07% |
| Aug 10 | $1.64 | $1.75 | $1.87 | -0.08% |
| Aug 11 | $1.63 | $1.75 | $1.88 | -0.10% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.63 | $1.75 | $1.88 | -0.10% |
| Week 2 | $1.58 | $1.75 | $1.93 | -0.20% |
| Week 3 | $1.54 | $1.74 | $1.98 | -0.29% |
| Week 4 | $1.51 | $1.74 | $2.01 | -0.39% |
| Week 5 | $1.48 | $1.74 | $2.05 | -0.49% |
| Week 6 | $1.46 | $1.74 | $2.08 | -0.58% |
| Week 7 | $1.44 | $1.74 | $2.10 | -0.68% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Annovis Bio, Inc. is a clinical stage drug platform company that develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat Alzheimer's disease, as well as in open-label phase 3 to treat Parkinson's disease.
It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of Alzheimer’s disease and dementia. Annovis Bio, Inc. was incorporated in 2008 and is headquartered in Malvern, Pennsylvania.
Annovis Bio, Inc. (ANVS) is currently priced at $1.69 with a market cap of $71.9M and a rank of 4130. The stock trades in a volatile space reflective of its clinical-stage focus and the ongoing development of its lead and supporting candidates.
A major floor 16.8% below — a decisive break under it would weaken the trend.
The nearest floor, 5.7% below — buyers have tended to step in here.
The nearest ceiling, 13.7% above — a clean break opens room to run.
A major ceiling 37.1% above — clearing it would confirm fresh momentum.
Key ANVS support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ANVS market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.72 | Buy | $1.73 | Buy |
| MA 10 | $1.72 | Buy | $1.73 | Buy |
| MA 20 | $1.78 | Sell | $1.76 | Sell |
| MA 50 | $1.83 | Sell | $1.85 | Sell |
| MA 100 | $1.99 | Sell | $2.03 | Sell |
| MA 200 | $2.50 | Sell | $2.36 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 47.77 | Neutral |
| Stoch RSI (14) | 83.67 | Sell |
| CCI (20) | -25.20 | Neutral |
| Williams %R (14) | -35.71 | Info |
| MACD (12,26,9) | 0.00 | Buy |
| ROC (12) | -2.78 | Sell |
| Bollinger %B (20,2) | 0.42 | Neutral |
| Stochastic %K (14) | 64.29 | Neutral |
| TRIX (15) | -0.29 | Sell |
| Awesome (5,34) | -0.07 | Sell |
| Ultimate (7,14,28) | 50.88 | Neutral |
| Momentum (10) | 0.01 | Buy |
| Aroon Osc (25) | 32.00 | Buy |
| Hull MA (9) | 1.74 | Buy |
| ADX (14) | 12.26 | Neutral |
| ATR (14) | 0.04 | Info |
The 30-day technical picture is bearish at present, with RSI(14) at 40. The stock trades below the SMA50 of $1.91 and well below the SMA200 of $2.52. The immediate technical framework shows a support level at $1.65 and a resistance level at $1.99.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.59 | $1.75 | $2.15 | 0% | Neutral | |
| $1.66 | $2.09 | $2.77 | +19% | Neutral | |
| $1.80 | $2.33 | $3.20 | +33% | Bullish | |
| $1.80 | $2.37 | $3.36 | +35% | Bullish | |
| $1.76 | $2.38 | $3.45 | +36% | Bullish | |
| $1.71 | $2.35 | $3.48 | +34% | Bullish | |
| $1.80 | $2.52 | $3.81 | +44% | Bullish | |
| $1.95 | $2.77 | $4.27 | +58% | Bullish | |
| $2.20 | $3.18 | $4.97 | +82% | Bullish | |
| $2.40 | $3.52 | $5.59 | +101% | Bullish | |
| $2.80 | $4.39 | $7.41 | +151% | Bullish | |
| $4.41 | $7.75 | $14.32 | +343% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $1.59 | $1.75 | $2.11 | +0.00% |
| September 2026 | $1.45 | $1.72 | $2.09 | -1.91% |
| October 2026 | $1.45 | $1.73 | $2.12 | +0.66% |
| November 2026 | $1.47 | $1.76 | $2.19 | +2.03% |
| December 2026 | $1.43 | $1.72 | $2.15 | -2.37% |
Click any year to see its month-by-month ANVS forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The ANVS price prediction for 2026 points to an average of $1.75 (low $1.59, high $2.15) — a potential gain of 0% on today's $1.75. A consolidation phase looks the most probable path here.
In 2027, ANVS is projected to trade between $1.66 and $2.77, averaging $2.09 — a potential gain of +19% from today's $1.75. That is up +19% on the projected 2026 average. Price action looks broadly range-bound.
Annovis Bio, Inc.'s 2028 outlook centres on $2.33, within a $1.80 to $3.20 range. That is up +12% on the projected 2027 average. That marks a +33% change versus current levels. Buyers look set to stay in control over this stretch.
By 2029, ANVS could reach as high as $3.36, with a base case around $2.37 and support toward $1.80 — roughly +35% from $1.75. Momentum favours further upside here.
Expect ANVS to range from $1.76 to $3.45 through 2030. The $2.38 average target implies a +36% move from current prices. That is up 0% on the projected 2029 average. Buyers look set to stay in control over this stretch.
The ANVS price prediction for 2031 points to an average of $2.35 (low $1.71, high $3.48) — a potential gain of +34% on today's $1.75. Momentum favours further upside here.
In 2032, ANVS is projected to trade between $1.80 and $3.81, averaging $2.52 — a potential gain of +44% from today's $1.75. That is up +7% on the projected 2031 average. Buyers look set to stay in control over this stretch.
Annovis Bio, Inc.'s 2033 outlook centres on $2.77, within a $1.95 to $4.27 range. That is up +10% on the projected 2032 average. That marks a +58% change versus current levels. Momentum favours further upside here.
By 2034, ANVS could reach as high as $4.97, with a base case around $3.18 and support toward $2.20 — roughly +82% from $1.75. Buyers look set to stay in control over this stretch.
Expect ANVS to range from $2.40 to $5.59 through 2035. The $3.52 average target implies a +101% move from current prices. That is up +11% on the projected 2034 average. Momentum favours further upside here.
The ANVS price prediction for 2040 points to an average of $4.39 (low $2.80, high $7.41) — a potential gain of +151% on today's $1.75. Buyers look set to stay in control over this stretch.
In 2050, ANVS is projected to trade between $4.41 and $14.32, averaging $7.75 — a potential gain of +343% from today's $1.75. That is up +77% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in ANVS today (≈ 571.428571 ANVS) could be worth
$4,428.34
+$3,428.34 (+343%) by 2050 · US Dollar
Based on the average projected ANVS price of $7.75 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ANVSwould be worth at today's price.
$1,000 invested in ANVS on Jul 31, 2025 (≈ 366.300364 ANVS) would be worth
$641.03
-$358.97 (-35.9%) today · 0.64× · US Dollar
Based on a ANVS entry price of $2.73 vs. today's $1.75.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.66 | $1,054.22 | +5.4% |
| 1 month ago | $1.92 | $911.46 | -8.9% |
| 3 months ago | $2 | $875 | -12.5% |
| 6 months ago | $2.7 | $648.15 | -35.2% |
| 1 year ago | $2.73 | $641.03 | -35.9% |
| All time (5.0y) ago | $42.5 | $41.18 | -95.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ANVS forecast.
Our base-case forecast reaches $3.50 around 2035.
Implied market cap at $3.50: $148.9M
The multi-year forecast shows a bullish trajectory from 2027 onward, with the following annual averages and ROIs: 2026 avg $1.69, 0% ROI; 2027 avg $2.04, 20.6% ROI; 2028 avg $2.27, 34.2% ROI; 2029 avg $2.22, 31.4% ROI; 2030 avg $2.26, 33.9% ROI; 2031 avg $2.19, 29.7% ROI; 2032 avg $2.29, 35.4% ROI; 2033 avg $2.57, 52.1% ROI; 2034 avg $2.92, 72.5% ROI; 2035 avg $3.23, 91.2% ROI; 2040 avg $3.94, 133% ROI; 2050 avg $6.81, 302.7% ROI. The sentiment turns bullish across the forecast horizon with progressively higher averages and sizable ROIs, but these are estimates and not guarantees of future results and should be considered in the context of inherent clinical-stage investment risk.
Tap a question to reveal the answer.
2030 avg $2.26 with a max of $3.38 and a min of $1.64; ROI 33.9%; sentiment BULLISH.
Forecasts show a neutral outlook in 2026 and a bullish trend from 2027 onward, with average prices rising to $2.04 in 2027, $2.27 in 2028, $2.22 in 2029, $2.26 in 2030, and higher thereafter, with increasing ROIs.
Yes. The forecast shows a max of $5.31 in 2035 and higher later, with 2040 max $6.92 and 2050 max $13.18.
The current price is $1.69 and the market cap is $71.9M. It ranks 4130.
The 30-day range is from $1.38 to $2.07.
Annovis Bio, Inc. Community Discussion
0Share your Annovis Bio, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.